New drugs aim at a hard-to-treat lung cancer gene change
Original title: Towards better outcomes for epidermal growth factor receptor L858R+ lung cancer patients: mutant-selective allosteric inhibitors and the potential for double-drugging.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This looks across many earlier studies rather than running a new one.
This is an expert review of where the research is going, not a new result in patients.
The short version
Experts looked at new drugs being built for a lung cancer gene change called L858R.
What was studied. This is a review article, not a new study. Experts went over the work on next-generation EGFR drugs. They focused on a type called allosteric drugs, which grab a different spot on the receptor.
What they found. A drug called osimertinib is standard care today for these lung cancers, but the cancer often stops responding to it. People with the L858R change do not do as well as people with another EGFR change called an exon 19 deletion. A drug called EAI-432 can attach to the receptor at the same time as osimertinib, so both drugs work on it at once.
What this means, and what it doesn't
What it could mean: Someday doctors may have a two-drug combination for this lung cancer. That could matter for the brain, because this cancer often spreads there.
What it doesn't mean: This is a review of where the science is heading. It is not a new result, and it is not a test in patients. It does not show that two drugs together help people live longer or better. EAI-432 is not approved, and you cannot ask for it today. This is not a cure. Also, this is about lung cancer that can spread to the brain, not about tumors that start in the brain.
Source: PubMed, August 20, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.